BRD4 and cancer: Although small-molecule BRD4 inhibitors such as iBET, JQ1 and OTX015 have shown their preclinical anti-cancer potential by preventing the binding of BRD4 with acetylated chromatin, their lack of sustained inhibition leads to re-accumulation of BRD4 protein and limited suppression of key oncogenes and potentially inducing resistance [[19], [20], [21]].